Clinical Trials Logo

Clinical Trial Summary

The ideomotor theory of action control is considered to be central to the understanding of human voluntary action. According to the ideomotor theory, an action is represented in terms of its desired sensory effects and actions are selected by internally activating these effect representations. Recent imagery and behavioral studies showed that this anticipated representation of action-effects triggered a "sensory attenuation", meaning a decrease of perceptive performances or a decrease of sensory event-related potentials (ERP) for an expected event. Thus, the sensory attenuation constitutes a relevant behavioral tool to investigate sensory anticipation impairment in patients with Parkinson's disease. In a behavioral paradigm, patients and matched control participants have to perform a perceptive task on predicted visual action-effects mixed with mispredicted visual action effects. Performances should be better in mispredicted visual action effects for control participants only.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02894333
Study type Observational
Source Fondation Ophtalmologique Adolphe de Rothschild
Contact Laurence Salomon, MD
Phone +33 1 48 03 64 31
Email lsalomon@fo-rothschild.fr
Status Recruiting
Phase N/A
Start date December 2015
Completion date September 2019

See also
  Status Clinical Trial Phase
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Recruiting NCT03257046 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease Phase 1/Phase 2
Recruiting NCT03295786 - Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease Phase 1/Phase 2
Completed NCT03103399 - Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" Phenomenon Phase 2
Suspended NCT03104725 - Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease? N/A
Recruiting NCT03014050 - Bio Electro Stimulation Therapy for Parkinson's Disease N/A
Not yet recruiting NCT03439943 - Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease Phase 2
Not yet recruiting NCT03551392 - Pilot Intervention With Near Infrared Stimulation N/A
Recruiting NCT02823158 - Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM N/A
Recruiting NCT03192046 - Bracing for Walking in Parkinson's Disease N/A
Recruiting NCT02869945 - Compensation Mechanisms in Parkinson's Disease N/A
Recruiting NCT03045211 - Post-Physical Therapy Extension of In-Home Dynamic Standing Table Use in Parkinson Disease N/A
Recruiting NCT02385500 - Fesoterodine on Urgency Episodes in Parkinson's Disease Population Phase 4
Recruiting NCT02601586 - Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease Phase 2/Phase 3
Recruiting NCT03143374 - Positron Emission Tomography (PET) Imaging of Tau Pathology in Neurodegenerative Disease N/A
Recruiting NCT02897063 - Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Phase 1
Not yet recruiting NCT02855021 - Prediction of Dementia in Parkinson's Disease by Measuring Cerebral Metabolism With PET Scan N/A
Recruiting NCT03288909 - Ultra High Field Magnetic Resonance Imaging as a Biomarker for Premotor Parkinson's Disease N/A
Recruiting NCT02718560 - Handwriting Rehabilitation in Parkinson Disease N/A